Russia permanently registers Favipiravir for COVID-19 treatment
A drug called Favipiravir used to take care of COVID-19, has gainedpermanent registration in Russia, Russian Deputy Health Minister Viktor Fisenkosaid on Thursday, reports TASS.
No significant side effects of favipiravir recorded in Russia, Healthcare Ministry confirms .
He said "Carrying out a sped-up procedure, we havegreenlit circulation of prevention drugs (vaccines), antiviral therapy drugs -Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm -Levilimab,", adding that Favipiravir has received a permanent registrationcertificate.
Earlier, the Russian Federal Service for Surveillance inHealthcare informed that Russia had registered three drugs based onFavipiravir: Avifavir, Areplivir and Coronavirus.
The watchdog hasn't took any complaints of non-specificmotor disorders during the consumption of the drugs.
